Patents Examined by Patricia A. Duffy
  • Patent number: 11406578
    Abstract: The present invention relates to a process for stripping keratin fibres, and in particular human keratin fibres such as the hair, dyed with oxidation dyes and/or direct dyes, using a composition obtained by extemporaneous mixing of an anhydrous or aqueous composition (A) comprising at least one suitably selected sulfinic acid derivative and an aqueous composition (B) with a pH of less than (5), comprising at least one organic acid other than the compounds of formula (I), with a pKa of less than or equal to (4) when the composition (A) is aqueous, the pH of the mixture of the two compositions (A) and (B) being less than or equal to (5). The invention also relates to a composition for stripping the artificial colour from keratin fibres, comprising at least one suitably selected sulfinic acid derivative and at least one thickener chosen from anionic polymers and nonionic polymers.
    Type: Grant
    Filed: November 24, 2011
    Date of Patent: August 9, 2022
    Assignee: L'OREAL
    Inventors: Gautier Deconinck, Laure Jouffroy-Wendlinger, Sylvain Kravtchenko, Damarys Braida-Valerio
  • Patent number: 11400147
    Abstract: The present invention is in the field of pneumococcal capsular saccharide conjugate vaccines. Specifically, an immunogenic composition for infants is provided comprising a multivalent Streptococcus pneumoniae vaccine comprising 2 or more capsular saccharide conjugates from different serotypes, wherein the composition comprises a serotype 22F saccharide conjugate. Such a vaccine may be used in infant populations to reduce the incidence of elderly pneumococcal disease such as exacerbations of COPD and/or IPD.
    Type: Grant
    Filed: January 12, 2018
    Date of Patent: August 2, 2022
    Inventors: Ralph Leon Biemans, Nathalie Marie-Josephe Garcon, Philippe Vincent Hermand, Jan Poolman, Marcelle Paulette Van Mechelen
  • Patent number: 11395790
    Abstract: The aspects presented herein provide methods and compositions for the reduction of the peroxide value of perfume ingredients, formulated perfumes, formulated body care products, formulated skin care products, formulated homecare products, essential oils, food raw materials, formulated food products, and natural extracts.
    Type: Grant
    Filed: July 2, 2019
    Date of Patent: July 26, 2022
    Assignee: Firmenich SA
    Inventors: Michael J. Calandra, Ying Wang
  • Patent number: 11389518
    Abstract: Disclosed herein are Mycoplasma bovis immunogenic compositions useful in raising an immune response in animals against M. bovis. Also disclosed herein are methods for generating a protective response against infections in mammals caused by M. bovis.
    Type: Grant
    Filed: August 11, 2016
    Date of Patent: July 19, 2022
    Assignees: Zoetis Services LLC
    Inventors: Glenn Francis Browning, Philip Francis Markham, Marc Serge Marenda, Fred H. Weber, Suman Mahan
  • Patent number: 11376315
    Abstract: The present invention provides improved methods for producing a solution containing high molecular weight isolated Streptococcus pneumoniae capsular polysaccharides having phosphodiester linkages between saccharide repeat units. In certain methods, CO2 is supplied to a fermentation culture of Streptococcus pneumoniae bacterial cells that produce capsular polysaccharide serotypes containing phosphodiester linkages between saccharide repeat units. Exemplary Streptococcus pneumoniae serotypes containing a phosphodiester linkage between saccharide repeat units include serotypes 6A, 6B, 19A, and 19F. Supplying CO2 to the fermentation culture includes adding bicarbonate ions to the fermentation culture, adding carbonate ions to the fermentation culture, adding mixtures of bicarbonate and carbonate ions to the fermentation culture, and overlaying the fermentation culture with CO2.
    Type: Grant
    Filed: June 25, 2020
    Date of Patent: July 5, 2022
    Assignee: Wyeth LLC
    Inventor: Jean Heather Crinean
  • Patent number: 11375720
    Abstract: Some HBL and NHE enterotoxins are known to cause food-borne diseases in humans. Enterotoxin-deficient mutants of member strains of the Bacillus cereus group that do not produce HBL, HBLa1, HBLa2, or NHE enterotoxins are disclosed. Enterotoxin-deficient mutants are suitable for use as biocontrol agents. Methods for making the mutants and for using the mutants are described.
    Type: Grant
    Filed: June 11, 2018
    Date of Patent: July 5, 2022
    Inventors: Jo Emily Handelsman, Amy Klimowicz, Changhui Guan
  • Patent number: 11377637
    Abstract: The invention provides a T cell wherein one or more therapeutic transgenes is integrated at a within the genome of the cell such that expression of the transgene is under control of an endogenous promoter of the T cell. The invention additional provides methods of making and using such cells to treat a subject with T cell therapy. The invention also provides a T cell wherein a recombinant nucleic acid sequence encoding a chimeric antigen receptor (CAR) is integrated at a first site within the genome of the cell such that the CAR is expressed by the cell at the surface of the cell, and wherein integration of the nucleic acid encoding the CAR at the first site reduces or prevents expression of a functional T cell receptor (TCR) complex at the surface of the cell. The invention additional provides methods of making and using such cells to treat a subject with CAR therapy.
    Type: Grant
    Filed: April 14, 2017
    Date of Patent: July 5, 2022
    Assignee: Memorial Sloan Kettering Cancer Center
    Inventors: Michel W. J. Sadelain, Justin Gabriel Andre Francois Eyquem, Jorge Mansilla-Soto
  • Patent number: 11357860
    Abstract: A composition comprising intact killed bacterial cells that contain a therapeutic nucleic acid, a drug or a functional nucleic acid is useful for targeted delivery to mammalian cells. The targeted delivery optionally employs bispecific ligands, comprising a first arm that carries specificity for a killed bacterial cell surface structure and a second arm that carries specificity for a mammalian cell surface receptor, to target killed bacterial cells to specific mammalian cells and to cause endocytosis of the killed bacterial cells by the mammalian cells. Alternatively, the delivery method exploits the natural ability of phagocytic mammalian cells to engulf killed bacterial cells without the use of bispecific ligands.
    Type: Grant
    Filed: January 28, 2018
    Date of Patent: June 14, 2022
    Assignee: EngeneIC Molecular Delivery Pty Ltd
    Inventors: Himanshu Brahmbhatt, Jennifer MacDiarmid
  • Patent number: 11352426
    Abstract: The present disclosure relates to protein molecules that specifically bind to CD3, which may have at least one humanized CD3-binding domain. Such molecules are useful for the treatment of cancer. The protein molecule binding to CD3 may have a second binding domain that binds to another target. In one embodiment, multispecific polypeptide molecules bind both tumor antigen-expressing cells and the CD3 subunit of a T-cell receptor complex on T-cells to induce target-dependent T-cell cytotoxicity, activation, and proliferation. The disclosure also provides pharmaceutical compositions comprising the CD3-binding poypeptide molecules, nucleic acid molecules encoding these polypeptides and methods of making these molecules.
    Type: Grant
    Filed: September 21, 2016
    Date of Patent: June 7, 2022
    Inventors: Philip Tan, John W. Blankenship
  • Patent number: 11344502
    Abstract: Disclosed are controlled release particles including: (a) a core including at least one vitamin which is oil-soluble or oil-dispersible; and (b) a wall at least partially surrounding the core, wherein the controlled release particles are produced by reacting (i) a first composition including a hydrophobic oil, the at least one vitamin, an anti-oxidant and a wax with (ii) a second composition including a water soluble emulsifier, a corn protein and a solvent to form an intermediate product, which is mixed with (iii) a third composition including a cellulosic polymer in water, and dehydrated to provide the controlled release particles. A method for preparing the particles and compositions containing the particles are also disclosed.
    Type: Grant
    Filed: February 27, 2019
    Date of Patent: May 31, 2022
    Assignee: TRUCAPSOL LLC
    Inventors: Jiten Odhavji Dihora, Caroline Rachel Multari
  • Patent number: 11339367
    Abstract: Hyperblebbing Shigella strains are generated by disrupting one or more components of the Tol-Pal system. The blebs from these strains are useful immunogens for vaccination. The individual proteins found in these blebs can also be used as immunogens.
    Type: Grant
    Filed: April 8, 2016
    Date of Patent: May 24, 2022
    Inventors: Christiane Gerke, Francesco Berlanda Scorza, Allan Saul, Luana Maggiore
  • Patent number: 11318176
    Abstract: The present invention relates to a topical composition of facilitating wound healing and reducing scars, which includes an inactivated culture of Lactobacillus species as an effective ingredient and can significantly facilitate wound healing as well as reducing scars, thereby can be applied to a method of facilitating wound healing and reducing scars.
    Type: Grant
    Filed: August 13, 2019
    Date of Patent: May 3, 2022
    Assignee: GenMont Biotech Incorporation
    Inventors: Yi-Hsing Chen, Wan-Hua Tsai, Wen-Wei Chang, Chia-Hsuan Chou
  • Patent number: 11318162
    Abstract: Provided is a method or the like for producing a composition exhibiting cytocidal activity. This method for producing a composition exhibiting cytocidal activity comprises: culturing malignant tumor-derived cells in a culture medium at least until the cell density reaches a level that does not pose a problem for transfer; replacing, after culturing, the culture medium with a physiological buffer salt solution; and recovering the physiological buffer salt solution after death of the malignant tumor-derived cells is observed morphologically in the physiological buffer salt solution.
    Type: Grant
    Filed: October 5, 2018
    Date of Patent: May 3, 2022
    Assignee: Medical Corporation Ichikawa Clinic
    Inventors: Tomoyuki Tajima, Yoshifusa Kondo
  • Patent number: 11318160
    Abstract: Provided are compositions, methods, and solutions for generating aqueous glucomannan solutions with hydrogen compositions greater than 100 parts per billion. Said glucomannan solutions have application in nutritional, therapeutic, and energy fields.
    Type: Grant
    Filed: January 7, 2020
    Date of Patent: May 3, 2022
    Assignee: NUTRAGENOM, LLC
    Inventor: Eugene P. Pittz
  • Patent number: 11306137
    Abstract: Presented herein, in certain embodiments, are compositions comprising antibody binding agents that specifically bind to A. baumannii and inhibit and/or block A. baumannii infection, and uses thereof.
    Type: Grant
    Filed: July 13, 2016
    Date of Patent: April 19, 2022
    Assignee: Los Angeles BioMedical Research Institute at Harbor-UCLA Medical Center
    Inventors: Brad Spellberg, Kevin Bruhn, Travis Nielsen
  • Patent number: 11306138
    Abstract: This invention relates to recombinant human antibody molecules. The antibodies bind fungal antigens, for example from Candida spp. Human antibody encoding genes targeting clinically relevant Candida epitopes have been isolated from single B cells from carefully selected donors and screened with specified types of protein or cell wall extract. The panel of purified, fully human recombinant IgG1 mAbs generated displayed a diverse range of specific binding profiles and demonstrated efficacy in a disease model. The fully human mAbs and derivatives thereof have utility in the generation of diagnostics, therapeutics and vaccines.
    Type: Grant
    Filed: March 4, 2016
    Date of Patent: April 19, 2022
    Inventors: Neil Andrew Robert Gow, Fiona Marion Rudkin, Lars-Peter Erwig, Allan Jensen
  • Patent number: 11306147
    Abstract: The present invention relates to the field of biomedicine and antibody engineering. Specifically, it relates to mono and multispecific multivalent single chain polypeptide molecules and derivatives thereof, preferably to multispecific single chain (tandem) trimerbodies with defined stoichiometry, to nucleic acid sequences and vectors encoding thereof, and host cells expressing the same. It further relates to methods of producing thereof, pharmaceutical compositions, kits, methods of treatment, use as diagnostics or imaging reagents and combination therapies using thereof.
    Type: Grant
    Filed: December 9, 2016
    Date of Patent: April 19, 2022
    Assignee: Leadartis, S.L.
    Inventors: Luis Álvarez Vallina, Laura Sanz Alcober
  • Patent number: 11292808
    Abstract: The present invention relates to neisserial LPS having a hexa-acylated lipid A moiety, wherein the hexa-acylated lipid A moiety is modified as compared to the lipid A moiety of a wild-type neisserial LPS in that it comprises a palmitoleoyl instead of a lauroyl secondary acyl chain on the glucosamine at the non-reducing end of the lipid A moiety. The invention further relates to mixtures of the hexa-acylated LPS with the corresponding penta-acylated LPS, lacking a secondary acyl chain on the glucosamine at the non-reducing end of the lipid A moiety. The invention also relates to neisserial bacteria that have been genetically modified to reduce expression of the endogenous lpxL1 gene and to introduce expression of a heterologous thermosensitive lpxP gene for producing the hexa- and penta-acylated LPS.
    Type: Grant
    Filed: January 27, 2017
    Date of Patent: April 5, 2022
    Assignee: Intravacc B.V.
    Inventors: Afshin Zariri, Elder Pupo Escalona, Peter André Van Der Ley
  • Patent number: 11286307
    Abstract: Provided herein are plasma kallikrein antibodies binding to active plasma kallikrein and methods of using such antibodies in treating and preventing hereditary angioedema attack, such method may involve a first treatment period and optionally, a second treatment period. Also provided are methods of using such antibodies in treating hereditary angioedema involving a single dose of the antibody to a subject who has undergone a prior HAE treatment, followed by multiple doses of the same antibody if the subject experiences an HAE attack after the single dose.
    Type: Grant
    Filed: December 9, 2016
    Date of Patent: March 29, 2022
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Burt Adelman, Yung Chyung, Jennifer Schranz
  • Patent number: 11285201
    Abstract: A mutated Bordetella strain comprising at least a mutated ptx gene, a deleted or mutated dnt gene and a heterologous ampG gene is provided. The attenuated mutated Bordetella strain can be used in an immunogenic composition or a vaccine for the treatment or prevention of a Bordetella infection. Use of the attenuated Bordetella strain for the manufacture of a vaccine or immunogenic composition, as well as methods for protecting mammals against infection by Bordetella are also provided.
    Type: Grant
    Filed: February 11, 2020
    Date of Patent: March 29, 2022
    Inventors: Camille Locht, Nathalie Mielcarek, Anne-Sophie Debrie, Dominique Raze, Julie Bertout